Recently, the National Medical Products Administration (NMPA) approved the Class 1 innovative drug Nerandomilast Tablets (trade name: Jascayd) manufactured by Boehringer Ingelheim International GmbH for marketing. It is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adult patients. The marketing of this drug provides a new therapeutic option for patients.

　　(Source: NMPA website, Oct 28, 2025)